Production of the neutrophil-activating peptide (NAP)-l/IL-8 by mononuclear phagocytes from patients with RA and from control subjects was studied under various conditions. Mononuclear cells from bone marrow (BMMC), PBMC, and synovial fluid (SFMC) were cultured for up to 48 h in the absence or presence of Escherichia coli LPS, different interleukins, interferon-gamma, zymosan, or immune complexes, and the neutrophil-stimulating activity released into the culture medium was determined. As shown by neutralization with an antiserum raised against human recombinant NAP-1/IL-8, over 90% of this activity could be attributed to NAP-1/IL-S.
Introduction
Neutrophil migration and activation at inflammatory sites depend on a complex series of interrelated humoral and cellular control mechanisms that regulate the generation and expres-sion of neutrophil directed stimuli and modulate the activity of the responding cells. In RA, neutrophils migrating into the synovial membrane and the synovial fluid may be exposed to a number of mediators such as C5a formed upon complement activation (1) and several products secreted by endothelial and/ or mononuclear cells like platelet-activating factor, leukotriene B4 (2, 3) , IL-1, and tumor necrosis factor-alpha (TNF)' (4, 5) . Neutrophils contain a wide spectrum ofcartilage-degrading enzymes (6) which, upon stimulation, can be released along with cytotoxic oxygen metabolites. Activated neutrophils, therefore, may contribute, besides mononuclear phagocytes, chondrocytes, and other cells, to tissue damage at sites ofinflammation.
A novel monocyte-derived cytokine that specifically interacts with neutrophils has been described recently. Purification and sequence analysis studies performed in several laboratories led to the identification of a 72-amino acid peptide, that initially became known as MDNCF for monocyte-derived neutrophil chemotactic factor (7), MONAP for monocyte-derived neutrophil-activating peptide (8) and NAF for neutrophil-activating factor (9) . Presently the term neutrophil-activating peptide (NAP)-I/IL-8 is most widely accepted (10) . NAP-1/IL-8 presumably plays a major role in neutrophil diapedesis through vascular endothelium and focal recruitment at inflamed sites. This notion is supported by the observation that upon exposure to IL-1 or TNF, endothelial cells not only express adhesion proteins (1 1, 12 ) that promote their interaction with circulating neutrophils, but also produce NAP-1/IL-8 (13, 14) . In addition, human fibroblasts express NAP-1 /IL-8 mRNA in response to IL-1 or TNF (15) , and human synovial cells release neutrophil-stimulating activity when challenged with IL-1 (16) . NAP-I /IL-8 is also effective in vivo. Intradermal injection in rabbits results in plasma exudation and massive neutrophil infiltration (17) . Similar observations were made in rats, mice, guinea pigs, and dogs (Zwahlen, R., et al., manuscript in preparation).
We have studied the production ofNAP- (20) and by the monoclonal antibody Leu M3 (Becton Dickinson, Heidelberg, FRG). Monocyte content was 16-28% in PBMC from healthy controls, 26-54% in PBMC, and 24-36% in SFMC from RA patients. Routinely, total mononuclear cell fractions were cultured. In a few selected experiments isolated monocytes prepared by adherence (25) were also used.
Culture conditions. The culture medium consisted of DMEM supplemented with 100 IU/mI penicillin/streptomycin (Gibco AG, Basel, Switzerland), 25 mM NaHCO3, 20 were then transferred to a second plate for determination ofneutrophilstimulating activity, and stored at -70'C until use. Where indicated, culturing was performed in the presence of various human recombinant cytokines. The following concentrations, which had previously been shown to induce optimum production of NAP-1/IL-8 in PBMC and SFMC, were used: IL-I-beta (10 ng/ml; Glaxo, Geneva, Switzerland), IL-2 (200 U/ml; Glaxo), granulocyte/macrophage colony-stimulating factor (GM-CSF) (100 U/ml; Sandoz Ltd., Basel, Switzerland), IL-3 (100 U/ml; Sandoz Ltd.), TNF-alpha (10 ng/ml; Hoffmann-La Roche Ltd., Basel, Switzerland), and IFN-gamma (100 U/ml; Biogen, Laupheim, FRG). In addition, E. coli LPS (100 ng/ml; Gibco AG), zymosan and/or C3b-opsonized zymosan (1 mg/ml; Sigma Chemical Co., Munich, FRG), and immune complexes (see below) were used as stimuli. In some experiments, polymyxin B (100 U/ml; Sigma Chemical Co.) was used to prevent possible LPS effects. Solutions were made in pyrogen-free PBS or saline.
Preparation of immune complexes. Immune complexes were freshly prepared for each experiment. Heat-aggregated IgG (IgG-IC) was obtained by heating 10 
Results
Spontaneous release ofneutrophil-stimulating activity. PBMC and SFMC were cultured for up to 48 h, and neutrophil-stimulating activity was determined in the medium. As shown in Fig.  1 A, the activity increased linearly in a time-dependent manner with PBMC from both healthy individuals and RA patients. The yield obtained with cells from RA patients was 3-to 10-fold higher than that of the controls and showed marked interindividual variations. Similar results were obtained with cultures of isolated monocytes instead of mononuclear cell fractions. By far the highest yields, however, were observed with the mononuclear cells from the synovial fluid. As shown by direct comparison, SFMC produced 6-10 times more neutrophil-stimulating activity than PBMC from the same RA patients ( Fig. 1 B) . In accordance with this finding, NAP-1/IL-8 was detected in the synovial fluid of six RA patients (0.2-5.0 pmol/ml).
Effect ofLPS. It has been repeatedly shown that LPS is one of the most potent inducers of NAP-l/IL-8 in human monocytes (10) . In this study we found that LPS also enhanced the production of neutrophil-stimulating activity by mononuclear cells from RA patients. LPS had maximum effects at concentrations of 1 ng/ml with cells from RA patients and 5-10 ng/ml with cells from control individuals, and was used routinely at 100 ng/ml. The LPS-dependent induction ofneutrophil-stimulating activity in mononuclear cells from different sources is shown in Fig. 2 . The response of bone marrow-derived cells was moderate and of similar extent for controls and RA patients. With PBMC the effect was more pronounced, and higher yields of neutrophil-stimulating activity were consistently obtained with PBMC from RA patients. The strongest responses were observed with SFMC. In each single experiment LPS significantly enhanced the production of neutrophilstimulating activity, and the degree of enhancement was independent of the level of spontaneous production.
Effects ofdifferent cytokines, immune complexes andphagocytosis. In order to identify mediators that might induce the production of neutrophil-stimulating activity within rheumatoid joints, PBMC and SFMC were cultured in the presence of a variety of cytokines that are known to be formed in the inflamed synovium. In addition, RF-IC, LPS, and zymosan particles were used as stimuli. As shown by the yield after 24 h and in particular after 48 h, RF-IC, LPS, zymosan, IL-1, IL-3, and GM-CSF are powerful inducers ofneutrophil-stimulating activity in PBMC both from control individuals and RA patients. Since similar effects were observed with either non-opsonized or C3b-opsonized zymosan, only data obtained with non-op- (Fig. 3 A) . In agreement with the results obtained with LPS, all stimuli were more effective on PBMC from RA patients than from healthy individuals. The difference was statistically significant in all cases. A similar pattern of responses was observed with SFMC with the notable exception of IFN-gamma which was inhibitory (Fig. 3 B) . In SFMC, RF-IC, IL-1, and LPS were the most effective stimuli.
In view ofthe high stimulatory effect of RF-IC, three different immune complex preparations (RF-IC, IC, IgG-IC) were compared in a further series ofexperiments. As shown in Table  I , all preparations were active, and similar effects were obtained with IC and IgG-IC as with RF-IC on PBMC from RA patients and normal controls.
To exclude the possibility of LPS contamination as a cause of stimulation, the effects of polymyxin B, added at 100 U/ml to immune complex, cytokine, and zymosan preparations, Spontaneous and LPS-induced release of neutrophilstimulating activity from BMMC, PBMC, and SFMC. BMMC from four control subjects (o) and RA patients (-), PBMC from eight control subjects (o) and RA patients (-), and SFMC from seven RA patients (*) were cultured for 48 h with or without 100 ng/ml LPS (left and right in each group, respectively). Significant differences were observed between spontaneous release by PBMC and SFMC (P < 0.05) and BMMC and PBMC (P < 0.001) from RA patients as well as between LPS-induced release by BMMC and PBMC from control subjects and RA patients (P < 0.005).
were studied. Polymyxin B decreased the effect of 100 ng/ml LPS by at least 80%, but did not influence the response to the other stimuli. Polymyxin B also did not affect the release of neutrophil-stimulating activity by control and RA PBMC in the absence of added stimuli (data not shown).
NAP-J/IL-8 identification. To show unequivocally that the neutrophil-stimulating activity in the culture supernatants corresponded to NAP-I /IL-8, neutralization experiments with an antiserum raised against hrNAP-l/IL-8 (anti-NAP-l/IL-8) were performed. As shown in Table II A, anti-NAP-l/IL-8 prevented elastase release by human neutrophils induced by hrNAP-l/IL-8, but not by FMLP or C5a, showing that it can be used to inactivate NAP-1/IL-8 selectively. The effect of anti-NAP-1/IL-8 on the neutrophil-stimulating activity in the culture supernatants of PBMC from five RA patients is shown in Table II B. On average, the antiserum inhibited the neutrophilstimulating activity that was released spontaneously or after stimulation with LPS, RF-IC, zymosan, or IL-1 between 92 and 99%. This indicates that virtually all neutrophil-stimulating activity released by the PBMC was due to NAP-1/IL-8.
Effect of IFN-gamma. When studying the responses to various cytokines, we were surprised to find that IFN-gamma, which is a generally accepted macrophage activator (23), decreased the spontaneous release ofneutrophil-stimulating activity by SFMC (Fig. 3 B) . This effect was also observed in stimulated PBMC. As shown in Fig. 4 , IFN-gamma inhibited the enhancing effect of LPS and IL-1 on the production of neutrophil-stimulating activity by PBMC from both RA patients and healthy controls.
Effect ofindomethacin andglucocorticoids. It is well known that the release and oxygenation of arachidonic acid is stimulated in monocytes from RA (24-28). We have, therefore, examined the effect of inhibition of prostaglandin synthesis (by indomethacin) and the presumed inhibition of phospholipase A2 (by dexamethasone) on the production of neutrophil-stimulating activity by PBMC. Indomethacin clearly enhanced the zymosan-induced release of neutrophil-stimulating activity from PBMC of normal individuals and RA patients (Fig. 5) . In unstimulated and LPS-stimulated PBMC the effect of indomethacin was minimal.
By contrast, as shown in Fig. 6 , the strong inductive effect of zymosan, in either control or RA PBMC, was almost totally inhibited by dexamethasone at concentrations ranging be- (Upper) PBMC from eight normal individuals (o) and eight RA patients (e) were cultured with or without the indicated agent for 48 h. Neutrophil-stimulating activity is presented as the difference between release from stimulated and unstimulated cells. Single values (circles) and means (columns) are shown. Statistical difference between effects on cells from normal controls and RA patients was P = 0.01 for IL-2, P < 0.05 for TNF, P < 0.001 for IFN-gamma, P = 0.02 for GM-CSF, P = 0.002 for IL-3, P = 0.01 for IL-1, P = 0.001 for LPS, P = 0.005 for zymosan, and P < 0.001 for RF-IC. (Lower) SFMC from six RA patients were incubated with or without the indicated agent for 48 h. Statistical difference between stimulated and spontaneous release of neutrophil-stimulating activity was P = 0.05 for IFN-gamma, P < 0.05 for IL-3, P < 0.02 for GM-CSF and zymosan, P = 0.005 for TNF, and P < 0.005 for LPS, IL-1, and RF-IC.
articularly to treat synovitis, we studied the release of neutrophil-stimulating activity by SFMC from 4 RA patients before and 2 wk after intraarticular injection of 5 mg betamethasonedipropionate and 2 mg betamethasone-disodiumphosphate. This treatment dramatically reduced the spontaneous and LPS-dependent release of neutrophil-stimulating activity and decreased the total number ofleukocytes as well as the percentage of neutrophils in the synovial fluid (Table III) .
Discussion
In this study NAP-1/IL-8 production by mononuclear cells from RA patients and healthy individuals was compared. It Our results suggest that rheumatoid factor-containing immune complexes and IL-1, which are produced in large amounts in the inflamed synovium (29) (30) (31) (32) , are likely to be important mediators of NAP-1/IL-8 generation in rheumatoid joints. The comparison ofthe yield ofNAP-1/IL-8 in cells from the bone marrow, peripheral blood, and synovial fluid indicates that differentiation and activation increase the capacity of the mononuclear phagocytes to produce NAP-I /IL-8. The high level of spontaneous NAP-1/IL-8 release by SFMC suggests that these cells are activated and that inducers are present in the synovial fluid. This notion is supported by the recent finding of appreciable amounts of NAP-1/IL-8 in synovial fluids from RA patients. Enhanced HLA-DR expression, another parameter of activation, has been observed in synovial fluid and synovial membrane mononuclear cells from arthritic joints (33-35).
In addition to C5a, which is generated mainly through immune complex-dependent complement activation, NAP-1/IL-8 must be considered a major mediator ofthe continuous accumulation and activation of neutrophils, which contributes to the amplification and perpetuation of the inflammatory process. Besides mononuclear phagocytes, fibroblasts and synoviocytes have been shown to produce NAP-1/IL-8 upon stimulation with IL-1 (10, 16, 36) , indicating that this neutrophil attractant is presumably also released by the resident cells of the inflamed joint. Since NAP-1/IL-8 is much more resistant to inactivation by peptidases and proteases than C5a (37), it is likely to retain its activity in the synovial fluid and to have a long lasting effect on neutrophil recruitment. In vivo studies in rabbits have shown that NAP-1/IL-8 is chemotactic for neutrophils for up to 10 h after intradermal injection (17, 38) . In this study, we confirmed that several cytokines are strong inducers of NAP-l/IL-8 production. Mononuclear cells from patients with rheumatoid arthritis produce high amounts of prostaglandins (23) (24) (25) . In this study, inhibition of cyclooxygenase by indomethacin tended to enhance the spontaneous and stimulated release of NAP-l/IL-8 by PBMC. This observation suggests that PGE2 and possibly other prostanoids may inhibit NAP-I/IL-8 production, and that, therefore, treatment of RA patients with nonsteroidal antiinflammatory drugs may favor neutrophil recruitment and activation. A quite different situation was obtained with dexamethasone, which almost completely inhibited phagocytosisinduced NAP-l/IL-8 at concentrations as low as l0-9 M. Accordingly, application ofintraarticular glucocorticoids resulted in a dramatic reduction of both spontaneous and stimulated NAP-I/IL-8 production by cultured SFMC obtained from the treated joints. The treatment also decreased the number of neuExp.1 Figure 6 . Effect of dexamethasone (DM). 
